Try a new search

Format these results:

Searched for:



Total Results:



Krustev, E; Hanly, J G; Chin, R; Buhler, K; Cardwell, F; Urowitz, M B; Gordon, C; Bae, S -C; Romero-Diaz, J; Sanchez-Guerrero, J; Bernatsky, S; Wallace, D J; Isenberg, D A; Rahman, A; Merrill, J T; Fortin, P R; Gladman, D D; Bruce, I N; Petri, M; Ginzler, E M; Dooley, M A; Ramsey-Goldman, R; Manzi, S; Jonsen, A; Alarcon, G S; Van, Vollenhoven R F; Aranow, C; Mackay, M; Ruiz-Irastorza, G; Lim, S; Inanc, M; Kalunian, K C; Jacobsen, S; Peschken, C A; Kamen, D L; Askanase, A; Buyon, J; Fritzler, M J; Clarke, A E; Choi, M Y
Objectives We previously reported in a single centre prevalent SLE cohort that antibodies against the cytokinesis-associated protein M-Phase Phosphoprotein 1 (anti-MPP-1) were associated with SLE-related cranial neuropathy (CN), a rare manifestation of neuropsychiatric SLE (NPSLE). The purpose of this study was to assess whether anti-MPP-1 is a biomarker for CN or other NPSLE manifestations using an international SLE inception cohort. Methods SLE patients fulfilling the updated 1997 ACR classification criteria for SLE were included. Anti-MPP-1 antibody testing was performed on baseline samples (within 15 months of diagnosis) or first annual assessment using an addressable laser bead immunoassay (ALBIA) with purified recombinant human protein with results expressed as median florescence units (MFU). Based on healthy controls, a dilution of >=1:500 MFU was considered positive. NPSLE manifestations occurring over the first 5 years of follow up were documented annually based on ACR case definitions using published NPSLE attribution rules1). The frequency of anti-MPP-1 positivity between patients with versus without each of the 19 NPSLE manifestations was compared using univariate logistic regression. For any NPSLE manifestations where anti-MPP-1 positivity differed between patients with versus without the manifestation, baseline demographic and clinical characteristics were compared using t-tests and twosample tests of proportions. For NPSLE manifestations associated with anti-MPP-1 positivity in the univariate analysis, multivariable logistic regression analysis using penalized maximum likelihood estimates was then performed to assess the relationship between anti-MPP-1 and the NPSLE manifestation, adjusting for age at anti-MPP-1 testing, female, White race/ethnicity, and significantly different baseline clinical characteristics. Results Seven hundred and ninety-five SLE patients were assessed; 29.8% were anti-MPP-1 positive, 88.7% female, and 52.1% White. The frequency of anti-MPP-1 positivity differed only for those with versus without CN (70.0% vs. 29.3%; odds ratio [OR] 5.16, 95%CI 1.44, 18.54) (table 1). Compared to patients without CN (n=785), patients with CN (n=10) were more likely to fulfill the ACR hematologic (difference: 23.9%, 95%CI 5.0%, 42.8%) and antinuclear antibody criteria (difference: 4.3%, 95%CI 2.9%, 5.8%) (table 2). (Table Presanted)In the multivariate analysis, anti-MPP-1 remained associated with CN (OR 5.24, 95%CI 1.44, 19.09) after adjusting for age at anti-MPP-1 testing, female, White race/ethnicity, hematologic disorder, and antinuclear antibody (table 3). Conclusion Anti-MPP-1 is a potential biomarker for CN. Although anti-MPP-1 is differentially expressed in a variety of neurological cells and tissues, the link to a pathogenic role requires further study
ISSN: 2053-8790
CID: 5513552

Outcomes among 6721 Hospitalized COVID-19 Patients across the New York City Public Hospital System: a Retrospective Cohort Study [Letter]

Caputo, Nicholas; Zhang, John; Chin, Robert; Meyers, Chad; Natsui, Shaw; Silvestri, David M; D'Amore, Jason Z
PMID: 33501525
ISSN: 1525-1497
CID: 4767262

Maximizing Interhospital Transfer Resources for Neurosurgical Patients

Schnurman, Zane; Chin, Robert; Fishkin, Edward R; Huang, Paul P
BACKGROUND: Delays in patient transfers are associated with worse outcomes for some neurosurgical conditions. One of the primary causes of transfer delay is lack of neurosurgery ICU bed availability. In this study, we characterize the results of implementing an interhospital transfer protocol to reduce unnecessary transfers and improve bed availability. METHODS: A transfer protocol was implemented in July 2012 at the Bellevue Hospital Department of Neurosurgery that screened for and prevented transfer of low-risk patients that were unlikely to require specialized inpatient neurosurgical care. The impact of this protocol was assessed with prospectively recorded data on all potential interhospital transfers from May 2011 through June 2016. RESULTS: Of the 1978 calls (regarding 1886 individual patients), 402 occurred prior to the implementation of the transfer protocol and 1576 occurred after. Prior to the protocol, 84.1% of transfer requests were accepted but 15.2% were subsequently denied for bed unavailability. After the protocol, a smaller share of transfer requests were accepted after protocol screening (71.8%, p<.001), but only 1.9% (p<.001) were subsequently denied because of bed unavailability. The diagnosis demographics changed significantly (p<.001), with a larger share of arriving transfers suffering from aneurysms or tumors after the protocol and a smaller share suffering from stenosis/disc disease without neurological symptoms. CONCLUSIONS: The transfer protocol implemented in this study allowed transfer determination based on the need for specialized neurosurgical care rather than chance unavailability of beds. Developing interhospital transfer protocols may be an effective strategy to efficiently allocate limited hospital resources and improve transfer systems.
PMID: 28549644
ISSN: 1878-8769
CID: 2575032